Eldecalcitol is a synthetic vitamin D analog and an active pharmaceutical ingredient belonging to the secosteroid class. It is structurally related to calcitriol and is designed to exert vitamin D receptor-mediated biological effects. Eldecalcitol has been developed primarily for the management of osteoporosis and related bone disorders.
Eldecalcitol is also known by the development code ED-71. It is a vitamin D3 analog with a hydroxyl group introduced at the 2β position of the vitamin D structure. This structural modification contributes to its distinctive pharmacological profile compared with conventional active vitamin D metabolites.
Eldecalcitol binds to the vitamin D receptor (VDR) and influences calcium and phosphate homeostasis and bone metabolism. Its biological effects have been studied in relation to bone mineralization, bone turnover and prevention of fractures in patients with osteoporosis.
Eldecalcitol API is a pharmaceutical active ingredient used in the development and manufacture of vitamin D analog-based medicines. It is particularly associated with pharmaceutical applications involving osteoporosis and bone health.
Eldecalcitol has been approved and marketed in Japan for the treatment of osteoporosis. Clinical studies have evaluated its effects on bone mineral density and fracture risk in patients with osteoporosis.
Eldecalcitol acts through the vitamin D receptor (VDR). Following receptor activation, vitamin D-responsive biological pathways are regulated, affecting calcium and phosphate metabolism and bone remodeling.
Its pharmacological effects are associated with regulation of bone turnover and improvement of bone mineral density, making it an important vitamin D analog in osteoporosis-related pharmaceutical applications.
Eldecalcitol is primarily associated with:
Eldecalcitol API should be manufactured and tested according to the applicable approved specification and pharmaceutical quality requirements.
Relevant quality attributes may include:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.2% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 1.0% |
| Melting Point | 150°C – 154°C |